{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:33:23Z","timestamp":1793716403978,"version":"4.6.1"},"reference-count":41,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"unspecified","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Young Elite Scientists Sponsorship Program by CAST","award":["YESS20220646"],"award-info":[{"award-number":["YESS20220646"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170779"],"award-info":[{"award-number":["82170779"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270804"],"award-info":[{"award-number":["82270804"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470792"],"award-info":[{"award-number":["82470792"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472822"],"award-info":[{"award-number":["82472822"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["2023AFB867"],"award-info":[{"award-number":["2023AFB867"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,3,17]]},"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bladder cancer (BLCA) is a challenging malignancy with a poor prognosis, particularly in muscle-invasive cases. Despite recent advancements in immunotherapy, response rates remain suboptimal. This study investigates the role of METTL3, an m6A RNA methylation \u201cwriter,\u201d in regulating the immune microenvironment of BLCA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Through bioinformatics analysis, we identified METTL3 as being associated with the formation of an immunosuppressive microenvironment in BLCA and poor response to immunotherapy. Subsequently, we silenced METTL3 expression in BLCA cells using short hairpin RNA (shRNA) or inhibited its function with STM2457. The effectiveness of these interventions in remodeling the BLCA tumor microenvironment (TME) was confirmed through animal experiments and flow cytometry. Mechanistically, RNA sequencing and methylated RNA immunoprecipitation (MeRIP) sequencing revealed the molecular pathways by which METTL3 regulates the TME. This was further validated using in vitro cell co-culture, immunoprecipitation, ELISA, and RNA degradation assays. The synergistic effect of METTL3 with anti-Programmed Cell Death Protein 1 (PD-1) treatment in BLCA was confirmed in both orthotopic and ectopic BLCA animal models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>METTL3 was found to increase CXCL5 levels and suppress CCL5 expression in an m6A-dependent manner, leading to increased recruitment of myeloid-derived suppressor cells (MDSCs) and reduced infiltration of CD8+T cells. Silencing METTL3 or inhibiting its function restored immune cell balance and significantly enhanced the efficacy of anti-PD-1 therapy. Clinically, METTL3 overexpression correlated with poor complete response rate to immune checkpoint inhibitors (ICIs) therapy, associated with an immunosuppressive microenvironment characterized by elevated MDSC levels and reduced CD8+T cell infiltration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings highlight METTL3 as a key regulator of the immune microenvironment in BLCA and a promising therapeutic target to improve immunotherapy outcomes. Targeting METTL3 could potentially enhance the efficacy of ICIs in patients with BLCA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2024-011108","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T21:05:26Z","timestamp":1744751126000},"page":"e011108","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":26,"title":["METTL3 promotes an immunosuppressive microenvironment in bladder cancer via m6A-dependent CXCL5\/CCL5 regulation"],"prefix":"10.1136","volume":"13","author":[{"given":"Yonghua","family":"Tong","sequence":"first","affiliation":[{"name":"Department of Urology, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Urology, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Urology, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Urology, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"He","sequence":"additional","affiliation":[{"name":"Department of Urology, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojie","family":"Shang","sequence":"additional","affiliation":[{"name":"Department of Urology, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Urology, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ejun","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Urology, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Urology, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Liang","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, Guangdong, China"},{"name":"Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8418-143X","authenticated-orcid":false,"given":"Kun","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Urology, Huazhong University of Science and Technology, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"key":"2026052108352447000_13.4.e011108.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"2026052108352447000_13.4.e011108.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2024.01.006"},{"key":"2026052108352447000_13.4.e011108.3","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076743","article-title":"Advances in diagnosis and treatment of bladder cancer","volume":"384","author":"Lopez-Beltran","year":"2024","journal-title":"BMJ"},{"key":"2026052108352447000_13.4.e011108.4","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.euo.2022.10.003","article-title":"Epidemiology, Screening, and Prevention of Bladder Cancer","volume":"5","author":"Lobo","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"2026052108352447000_13.4.e011108.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.01.006"},{"key":"2026052108352447000_13.4.e011108.6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17598"},{"key":"2026052108352447000_13.4.e011108.7","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.euo.2021.01.004","article-title":"Perioperative Immunotherapy in Muscle-invasive Bladder Cancer","volume":"4","author":"Tripathi","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"2026052108352447000_13.4.e011108.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034442"},{"key":"2026052108352447000_13.4.e011108.9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00004-8"},{"key":"2026052108352447000_13.4.e011108.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0488-6"},{"key":"2026052108352447000_13.4.e011108.11","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.trecan.2022.04.001","article-title":"Utilizing chemokines in cancer immunotherapy","volume":"8","author":"M\u00e4rkl","year":"2022","journal-title":"Trends Cancer"},{"key":"2026052108352447000_13.4.e011108.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-018-0007-y"},{"key":"2026052108352447000_13.4.e011108.13","doi-asserted-by":"publisher","DOI":"10.7150\/thno.58390"},{"key":"2026052108352447000_13.4.e011108.14","article-title":"Targeting the epigenome to reinvigorate T cells for cancer immunotherapy","volume":"10","author":"Xiong","year":"2023","journal-title":"Mil Med Res"},{"key":"2026052108352447000_13.4.e011108.15","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adg3736","article-title":"Monocytic MDSCs exhibit superior immune suppression via adenosine and depletion of adenosine improves efficacy of immunotherapy","volume":"9","author":"Sarkar","year":"2023","journal-title":"Sci Adv"},{"key":"2026052108352447000_13.4.e011108.16","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1038\/s42255-022-00676-9","article-title":"Myeloid-derived itaconate suppresses cytotoxic CD8+ T cells and promotes tumour growth","volume":"4","author":"Zhao","year":"2022","journal-title":"Nat Metab"},{"key":"2026052108352447000_13.4.e011108.17","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-020-0666-9"},{"key":"2026052108352447000_13.4.e011108.18","doi-asserted-by":"publisher","DOI":"10.1038\/nrm.2016.132"},{"key":"2026052108352447000_13.4.e011108.19","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-020-0253-2"},{"key":"2026052108352447000_13.4.e011108.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.05.045"},{"key":"2026052108352447000_13.4.e011108.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.02.004"},{"key":"2026052108352447000_13.4.e011108.22","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-022-01558-0","article-title":"Targeting the RNA m6A modification for cancer immunotherapy","volume":"21","author":"Li","year":"2022","journal-title":"Mol Cancer"},{"key":"2026052108352447000_13.4.e011108.23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.802049","article-title":"The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors","volume":"12","author":"Tong","year":"2021","journal-title":"Front Immunol"},{"key":"2026052108352447000_13.4.e011108.24","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1158\/0008-5472.CAN-22-2485","article-title":"The m6A Reader YTHDF2 Promotes Bladder Cancer Progression by Suppressing RIG-I-Mediated Immune Response","volume":"83","author":"Zhang","year":"2023","journal-title":"Cancer Res"},{"key":"2026052108352447000_13.4.e011108.25","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-020-00951-w","article-title":"Roles of METTL3 in cancer: mechanisms and therapeutic targeting","volume":"13","author":"Zeng","year":"2020","journal-title":"J Hematol Oncol"},{"key":"2026052108352447000_13.4.e011108.26","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-019-1036-9","article-title":"METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221\/222 maturation in m6A-dependent manner","volume":"18","author":"Han","year":"2019","journal-title":"Mol Cancer"},{"key":"2026052108352447000_13.4.e011108.27","doi-asserted-by":"crossref","first-page":"110971","DOI":"10.1016\/j.cellsig.2023.110971","article-title":"METTL3 regulates the proliferation, metastasis and EMT progression of bladder cancer through P3H4","volume":"113","author":"Liu","year":"2024","journal-title":"Cell Signal"},{"key":"2026052108352447000_13.4.e011108.28","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-21-1323"},{"key":"2026052108352447000_13.4.e011108.29","doi-asserted-by":"publisher","DOI":"10.1146\/ANNUREV-PATHOL-042020-042741"},{"key":"2026052108352447000_13.4.e011108.30","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009865","article-title":"METTL3-VISTA axis-based combination immunotherapy for APC truncation colorectal cancer","volume":"12","author":"Wu","year":"2024","journal-title":"J Immunother Cancer"},{"key":"2026052108352447000_13.4.e011108.31","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.06.024"},{"key":"2026052108352447000_13.4.e011108.32","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202400695","article-title":"M6A-mediated upregulation of lncRNA TUG1 in liver cancer cells regulates the antitumor response of CD8+ T cells and phagocytosis of macrophages","volume":"11","author":"Xi","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"2026052108352447000_13.4.e011108.33","doi-asserted-by":"crossref","DOI":"10.1038\/s41420-022-01037-x","article-title":"circDHTKD1 promotes lymphatic metastasis of bladder cancer by upregulating CXCL5","volume":"8","author":"Lu","year":"2022","journal-title":"Cell Death Discov"},{"key":"2026052108352447000_13.4.e011108.34","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-024-03122-8","article-title":"CXCL5 impedes CD8+ T cell immunity by upregulating PD-L1 expression in lung cancer via PXN\/AKT signaling phosphorylation and neutrophil chemotaxis","volume":"43","author":"Sun","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"2026052108352447000_13.4.e011108.35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001162","article-title":"Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor","volume":"9","author":"Toh","year":"2011","journal-title":"PLoS Biol"},{"key":"2026052108352447000_13.4.e011108.36","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.bbrc.2018.03.071","article-title":"CXCL5 promotes mitomycin C resistance in non-muscle invasive bladder cancer by activating EMT and NF-\u03baB pathway","volume":"498","author":"Wang","year":"2018","journal-title":"Biochem Biophys Res Commun"},{"key":"2026052108352447000_13.4.e011108.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.05.004"},{"key":"2026052108352447000_13.4.e011108.38","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-023-02637-2"},{"key":"2026052108352447000_13.4.e011108.39","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-41218-5","article-title":"AhR diminishes the efficacy of chemotherapy via suppressing STING dependent type-I interferon in bladder cancer","volume":"14","author":"Ma","year":"2023","journal-title":"Nat Commun"},{"key":"2026052108352447000_13.4.e011108.40","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15207","article-title":"Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-\u03b3-induced immunologic dormancy of tumor-repopulating cells","volume":"8","author":"Liu","year":"2017","journal-title":"Nat Commun"},{"key":"2026052108352447000_13.4.e011108.41","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/s41586-021-03536-w","article-title":"Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia","volume":"593","author":"Yankova","year":"2021","journal-title":"Nature New Biol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-011108","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:35:41Z","timestamp":1779377741000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-011108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":41,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,15]]},"published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1136\/jitc-2024-011108"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-011108","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]}}}